Wan... sorry to take issue here, but I have not seen any factual research published on this site (or any other) that 'proves' Metrika's product to be sub-standard in terms of accuracy
We don't know whether A1cNow will pass the current NGSP certification standard because they don't have to re-submit data until June of 2003. They are still able to claim NGSP certification, however. In any event, you only have to look at the technical specification of the instrument in the manual to see that its operational tolerances are likely to ensure it will be re-certified later in the summer.
Also, in-home testing is the holy grail for all of these regular use, diagnostic products, from the manufacturers, clinicians and patients point of view. If A1cNow is addressing this market currently, in addition to the broader market, then it is difficult to see why it should be dismissed as a competitor product. After all, Glycosal is not in the home testing market, G5 has not got off the starting blocks yet, and MicroG is still years away from market.
As for price, it is a complex issue. Firstly, it depends who is ultimately paying the bill - the patient or Medicare. Secondly, many companies have led the field with rock bottom, market penetrating prices, only to end up making a loss.
Pros stock quotes
Pros stock charts
Follow this thread
